Ranibizumab
Indication
Age-related macular degeneration (NICE TA155)
NICE TA155 - Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
Brand:
Lucentis®
Nice TA:
155
Commissioning responsibility:
CCG
PbR excluded:
Yes
Background
LSCMMG is adopting the local decision made prior to April 2013
1.1 Ranibizumab, within its marketing authorisation, is recommended as an option for the treatment of wet age-related macular degeneration if:
all of the following circumstances apply in the eye to be treated:
-
the best-corrected visual acuity is between 6/12 and 6/96
-
there is no permanent structural damage to the central fovea
-
the lesion size is less than or equal to 12 disc areas in greatest linear dimension
-
there is evidence of recent presumed disease progression (blood vessel growth, as indicated by fluorescein angiography, or recent visual acuity changes)
and
-
the manufacturers of ranibizumab (branded or biosimilar) only provide it at a discount level no lower than the discount agreed in the patient access scheme.